271 related articles for article (PubMed ID: 8911260)
1. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group.
Christou NV; Turgeon P; Wassef R; Rotstein O; Bohnen J; Potvin M
Arch Surg; 1996 Nov; 131(11):1193-201. PubMed ID: 8911260
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group.
Barie PS; Vogel SB; Dellinger EP; Rotstein OD; Solomkin JS; Yang JY; Baumgartner TF
Arch Surg; 1997 Dec; 132(12):1294-302. PubMed ID: 9403533
[TBL] [Abstract][Full Text] [Related]
3. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
Donahue PE; Smith DL; Yellin AE; Mintz SJ; Bur F; Luke DR
Am J Surg; 1998 Dec; 176(6A Suppl):53S-61S. PubMed ID: 9935258
[TBL] [Abstract][Full Text] [Related]
4. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
5. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
6. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C;
Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
[TBL] [Abstract][Full Text] [Related]
7. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A; Meli EZ; Mazzocchi P; Speranza V
Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
[TBL] [Abstract][Full Text] [Related]
8. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
[TBL] [Abstract][Full Text] [Related]
9. [Evidence-based medicine, health costs and treatment of intra-abdominal infection].
Badía X; Brosa M; Tellado JM
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():86-94. PubMed ID: 10605193
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.
Walters DJ; Solomkin JS; Paladino JA
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):551-61. PubMed ID: 10662480
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
Youssif E; Aseeri M; Khoshhal S
J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
[TBL] [Abstract][Full Text] [Related]
12. Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis.
Tally FP; Gorbach SL
Am J Med; 1985 Jun; 78(6A):145-53. PubMed ID: 3890535
[TBL] [Abstract][Full Text] [Related]
13. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.
Solomkin JS; Wilson SE; Christou NV; Rotstein OD; Dellinger EP; Bennion RS; Pak R; Tack K
Ann Surg; 2001 Jan; 233(1):79-87. PubMed ID: 11141229
[TBL] [Abstract][Full Text] [Related]
14. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.
Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P
J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636
[TBL] [Abstract][Full Text] [Related]
15. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
Cox CE; Holloway WJ; Geckler RW
Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
[TBL] [Abstract][Full Text] [Related]
16. Impact an anatomical site on bacteriological and clinical outcome in the management of intra-abdominal infections.
Wilson SE; Faulkner K
Am Surg; 1998 May; 64(5):402-7. PubMed ID: 9585772
[TBL] [Abstract][Full Text] [Related]
17. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
18. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.
Brismar B; Akerlund JE; Sjöstedt S; Johansson C; Törnqvist A; Bäckstrand B; Bång H; Andåker L; Gustafsson PO; Darle N; Angerås M; Falk A; Tunevall G; Kasholm-Tengve B; Skau T; Nyström PO; Gasslander T; Hagelbäck A; Olsson-Liljequist B; Eklund AE; Nord CE
Scand J Infect Dis; 1996; 28(5):507-12. PubMed ID: 8953683
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.
Fomin P; Koalov S; Cooper A; Babinchak T; Dartois N; De Vane N; Castaing N; Tellado J;
J Chemother; 2008 Oct; 20 Suppl 1():12-9. PubMed ID: 19036670
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan.
Takesue Y; Kusachi S; Mikamo H; Sato J; Watanabe A; Kiyota H; Iwata S; Kaku M; Hanaki H; Sumiyama Y; Kitagawa Y; Nakajima K; Ueda T; Uchino M; Mizuguchi T; Ambo Y; Konosu M; Ishibashi K; Matsuda A; Hase K; Harihara Y; Okabayashi K; Seki S; Hara T; Matsui K; Matsuo Y; Kobayashi M; Kubo S; Uchiyama K; Shimizu J; Kawabata R; Ohge H; Akagi S; Oka M; Wakatsuki T; Suzuki K; Okamoto K; Yanagihara K
J Infect Chemother; 2018 May; 24(5):330-340. PubMed ID: 29555391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
